Baqsimi® (glukagon näspulver): Farmakokinetik

Detailed Information

Absorption

Glucagon absorption via the nasal route achieved mean peak plasma levels of 6130 pg/mL at 15 minutes.¹

Bioavailability

In an insulin-induced hypoglycemia study in adults with T1DM, the mean total plasma glucagon exposure after 3 mg NG was approximately 80% of that observed with 1 mg IM glucagon. This suggests that the relative bioavailability of NG is about 25% to 30% of IM glucagon.² 

Distribution

The apparent volume of distribution of glucagon was approximately 885 L via the nasal route.¹

Metabolism

Glucagon is known to be degraded in the liver, kidneys, and plasma.¹

Elimination

The mean half-life of glucagon was approximately 38 minutes via the nasal route.¹

Pediatrics

In paediatric patients (4 to < 17 years), glucagon absorption via the nasal route, achieved mean peak plasma levels between 15 and 20 minutes.¹

The median half-life was 21 to 31 minutes via the intranasal route.²

Special Populations

No formal studies have been performed to evaluate renal or hepatic impairment.¹

Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacokinetics via the nasal route.¹

References

1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

IM = intramuscular

NG = nasal glucagon (glucagon nasal powder)

PK = pharmacokinetic

T1DM = type 1 diabetes mellitus